Innovative Medicines Initiative, Brussels, Belgium.
Altern Lab Anim. 2012 Dec;40(6):307-12. doi: 10.1177/026119291204000603.
Animal models are still widely used to assess the efficacy or safety of new pharmaceutical products. Since their limitations in predicting actions of drugs in humans are becoming more and more apparent, there is an urgent need to revisit the use of animals in pharmaceutical research. Herein, we review how the Innovative Medicines Initiative (IMI), the largest public-private partnership in the life sciences, is reducing, refining and replacing the use of animals in the context of its global mission, namely, to boost research and the development of new medicines across the European Union.
动物模型仍然被广泛用于评估新药物产品的疗效或安全性。由于它们在预测药物在人体中的作用方面的局限性越来越明显，因此迫切需要重新审视动物在药物研究中的应用。本文综述了创新药物倡议（IMI），即生命科学领域最大的公私合作伙伴关系，如何在其全球使命的背景下减少、优化和替代动物的使用，该使命旨在促进整个欧盟的新药研究和开发。
